By Chris Wack
Rezolute shares were up 29%, to $4, after the company said an independent data monitoring committee recommended the continuation of a Phase 3 Ersodetug study in patients with congenital hyperinsulinism without an increase in the study sample size.
The biopharmaceutical company said it expects to complete enrollment next month, with topline results anticipated in December.
The interim analysis of the Phase 3 study was based on a pre-specified analysis of the primary study endpoint--hypoglycemia events--after half of enrolled patients completed the primary assessments.
Rezolute said the analysis was intended to evaluate for study a potential sample size increase, for purposes of optimizing the study power and statistical confidence in the final analysis outcomes.
Rezolute also said an underwritten offering of 20.8 million shares priced at $3.25 a share. Pre-funded warrants to buy up to 6.9 million shares priced at $3.249 per pre-funded warrant. Proceeds from the underwritten offering before deducting underwriting discounts and commissions and other offering expenses are expected to be $90 million.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
April 23, 2025 10:44 ET (14:44 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.